ES2151903T3 - Uso de manosa fosfatos para el tratamiento de trastornos fibroticos. - Google Patents

Uso de manosa fosfatos para el tratamiento de trastornos fibroticos.

Info

Publication number
ES2151903T3
ES2151903T3 ES93906680T ES93906680T ES2151903T3 ES 2151903 T3 ES2151903 T3 ES 2151903T3 ES 93906680 T ES93906680 T ES 93906680T ES 93906680 T ES93906680 T ES 93906680T ES 2151903 T3 ES2151903 T3 ES 2151903T3
Authority
ES
Spain
Prior art keywords
pct
phosphates
treatment
fibrotic disorders
manosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906680T
Other languages
English (en)
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2151903T3 publication Critical patent/ES2151903T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LOS 6- Y 1-FOSFATOS DE MANOSA Y SUS SALES FARMACEUTICAMENTE ACEPTABLES Y BIOPRECURSORES DE LOS MISMOS SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS FIBROTICOS. ACELERAN LA CICATRIZACION DE LAS HERIDAS Y EL 6-FOSFATO EVITA O MITIGA LA FORMACION DE CICATRICES. EN LA INVENCION SE PRESENTAN EN PARTICULAR FORMULACIONES APROPIADAS DEL FOSFATO DE MANOSA.
ES93906680T 1992-03-17 1993-03-16 Uso de manosa fosfatos para el tratamiento de trastornos fibroticos. Expired - Lifetime ES2151903T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929205800A GB9205800D0 (en) 1992-03-17 1992-03-17 Treatment of fibrotic disorders

Publications (1)

Publication Number Publication Date
ES2151903T3 true ES2151903T3 (es) 2001-01-16

Family

ID=10712310

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906680T Expired - Lifetime ES2151903T3 (es) 1992-03-17 1993-03-16 Uso de manosa fosfatos para el tratamiento de trastornos fibroticos.

Country Status (18)

Country Link
US (1) US5520926A (es)
EP (1) EP0728006B1 (es)
JP (1) JP3930556B2 (es)
AT (1) ATE196847T1 (es)
AU (1) AU667887B2 (es)
CA (1) CA2130805C (es)
DE (1) DE69329559T2 (es)
DK (1) DK0728006T3 (es)
ES (1) ES2151903T3 (es)
GB (2) GB9205800D0 (es)
GR (1) GR3035117T3 (es)
IL (1) IL105079A (es)
NO (1) NO306808B1 (es)
NZ (1) NZ249915A (es)
PT (1) PT728006E (es)
SG (1) SG49899A1 (es)
WO (1) WO1993018777A1 (es)
ZA (1) ZA931869B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
SE9403137D0 (sv) * 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
GB9616896D0 (en) * 1996-08-12 1996-09-25 British Tech Group Pharmaceutical compositions
DE19758059C2 (de) * 1997-12-29 2001-10-04 Thorsten Marquardt Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie
US7255883B2 (en) * 2000-06-23 2007-08-14 Healagenics, Inc. Agent for reduction of scar formation by using wound alkalinization
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20030031689A1 (en) * 2001-08-09 2003-02-13 Thomas Mammone Method of skin exfoliation
US6822033B2 (en) 2001-11-19 2004-11-23 United States Gypsum Company Compositions and methods for treating set gypsum
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
US20050142208A1 (en) * 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
KR100492913B1 (ko) * 2002-08-23 2005-06-03 주식회사 태평양 피부 감작 및 자극을 완화하는 피부 외용제 조성물
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (ja) * 2003-05-16 2011-02-16 花王株式会社 ビタミンｄ様活性代替用剤
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2538265T3 (es) 2006-10-03 2015-06-18 Genzyme Corporation Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
US8070895B2 (en) 2007-02-12 2011-12-06 United States Gypsum Company Water resistant cementitious article and method for preparing same
US8329308B2 (en) 2009-03-31 2012-12-11 United States Gypsum Company Cementitious article and method for preparing the same
GB0910078D0 (en) * 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916334D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
GB0916333D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Improvement of tendon repair
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
WO2012087434A2 (en) * 2010-11-05 2012-06-28 Healthypharma, Llc Use of phosphoric acid
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
EP3064222B1 (en) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2023172636A1 (en) * 2022-03-08 2023-09-14 University Of Mississippi Medical Center Articles and methods for improved tissue healing
CN115260256A (zh) * 2022-07-22 2022-11-01 河南中医药大学 一种甘露糖磷酸化衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756953A (fr) * 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
JPS5631156B2 (es) * 1973-09-25 1981-07-20
IT1170618B (it) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
EP0221728B1 (en) * 1985-10-22 1992-07-15 Anthony N. Silvetti, Sr. Monosaccharide containing wound healing preparation
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (ja) * 1986-04-15 1987-10-24 Kao Corp ｐＨ緩衝法
DE68926746T2 (de) * 1988-08-19 1996-11-28 Univ Australian Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
GB8917414D0 (en) * 1989-07-29 1989-09-13 Translift Material Handling Narrow aisle lift truck
JPH0780780B2 (ja) * 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
SE8904354D0 (sv) * 1989-12-21 1989-12-21 Matti Siren A pharmaceutical composition
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0558868A (ja) * 1991-08-27 1993-03-09 Kao Corp 親水性紫外線吸収剤及びこれを含有する化粧料
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JPH09155319A (ja) * 1995-12-13 1997-06-17 Takeo Tsutsui 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法

Also Published As

Publication number Publication date
DE69329559T2 (de) 2001-05-31
PT728006E (pt) 2001-04-30
GR3035117T3 (en) 2001-03-30
AU667887B2 (en) 1996-04-18
AU3759093A (en) 1993-10-21
NZ249915A (en) 1996-08-27
DK0728006T3 (da) 2000-10-30
US5520926A (en) 1996-05-28
NO943451L (no) 1994-09-16
IL105079A (en) 1998-06-15
CA2130805A1 (en) 1993-09-30
CA2130805C (en) 2003-06-24
DE69329559D1 (de) 2000-11-16
JP3930556B2 (ja) 2007-06-13
NO306808B1 (no) 1999-12-27
GB2265310A (en) 1993-09-29
SG49899A1 (en) 1998-06-15
JPH07504909A (ja) 1995-06-01
EP0728006B1 (en) 2000-10-11
ZA931869B (en) 1994-09-16
GB9205800D0 (en) 1992-04-29
NO943451D0 (no) 1994-09-16
EP0728006A1 (en) 1996-08-28
ATE196847T1 (de) 2000-10-15
GB9305344D0 (en) 1993-05-05
IL105079A0 (en) 1993-07-08
WO1993018777A1 (en) 1993-09-30
GB2265310B (en) 1996-09-25

Similar Documents

Publication Publication Date Title
ES2151903T3 (es) Uso de manosa fosfatos para el tratamiento de trastornos fibroticos.
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
AU5144396A (en) Trisubstituted phenyl derivatives
GB9521608D0 (en) Pharmaceutical composition
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
PT841937E (pt) Utilizacao de betaglicano para reduzir a formacao de cicatrizes
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
FI952855A0 (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
BG102009A (en) Method for the treatment of manic and two-pole disease

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 728006

Country of ref document: ES